October #75 : The Brits Are Revolting - by John Hatchett

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Vagina Monologues

A Negative Exposure

A Dangerous Age

Dissing Disability Queens

POTUS Priorities

Hat Trick

The Chastity Beltway

Burn in Helms

CALL TO ACTION

Exchange Suit

Piece of Pie

Mama Bear

Naked Eye

Rock Steady

Hip-Hop Hope

The Viral Lode

Rent Checked

D.I.Y. Thoreau

Shingles Scene

The Brits Are Revolting

U.K./U.S. Orals

Chronic Fatigue

Pulp Friction

Snapshots: Rebekka Armstrong

Mailbox

Butt Out

Wart's Up?



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

October 2001

The Brits Are Revolting

by John Hatchett

The WhiteCoats are coming! In the newest volley in the revolution against the "hit early, hit hard" rule, the British HIV Association (BHIVA) issued revised guidelines for when to start HAART that are decidedly more conservative than the "reverse course!" trumpeted by the U.S. in February. The Brits now recommend that symptom-free HIVers with CD4-cell counts from 200 to 350 (350 is the U.S. marker) take the cocktail only if their viral load is above 100,000 (30,000 in the U.S.) or their CD4 cells fall by more than 80 in one year.

This year's official retreat from early intervention on both sides of the pond is widely viewed as a case of catch-up with recent clinical practice, as more and more HIVers and their docs -- alarmed by HAART toxicities and viral resistance -- delay starting or take breaks from treatment. Yet the dearth of definitive "when to start" data -- there's still no large-scale clinical trial -- renders any recommendation questionable. Predictably, some Yankee researchers pooh-poohed the lower Brit numbers, pointing to stats showing a long-term survival benefit of earlier treatment. But BHIVA defends its "Patience, patients!" approach as the best way for HIVers signing on to lifelong HAART to minimize its curses -- side effects, adherence demands, drug resistance and failure -- while maximizing its blessings. Call it the British T (cell) Party.

-- John Hatchett

NEW RX GUIDELINES
When To Start HAART
U.S. U.K.
< 350 CD4s < 200 CD4s
or or
> 350 CD4s and
> 55,000 Viral Load (PCR)*
< 350 CD4s and
> 100,000 Viral Load (PCR)*
  or
*PCR is the most common VL test; bDNA tests, which score lower, are less sensitive. Ask your doctor. < 350 CD4s and
> 80 CD4s/year




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.